Your browser is no longer supported. Please, upgrade your browser.
NVS Novartis AG daily Stock Chart
Novartis AG
Index- P/E29.29 EPS (ttm)2.77 Insider Own9.30% Shs Outstand2.69B Perf Week1.84%
Market Cap218.72B Forward P/E15.51 EPS next Y5.23 Insider Trans0.38% Shs Float2.58B Perf Month2.10%
Income6.72B PEG4.74 EPS next Q1.18 Inst Own10.20% Short Float0.19% Perf Quarter12.07%
Sales50.00B P/S4.37 EPS this Y-33.30% Inst Trans1.48% Short Ratio2.29 Perf Half Y-4.21%
Book/sh30.19 P/B2.69 EPS next Y8.81% ROA5.10% Target Price92.50 Perf Year-14.23%
Cash/sh- P/C- EPS next 5Y6.17% ROE8.90% 52W Range68.87 - 102.83 Perf YTD-1.97%
Dividend2.72 P/FCF154.57 EPS past 5Y-7.50% ROI7.80% 52W High-20.85% Beta0.60
Dividend %3.35% Quick Ratio0.60 Sales past 5Y-0.50% Gross Margin65.30% 52W Low18.18% ATR1.44
Employees118000 Current Ratio0.80 Sales Q/Q-3.00% Oper. Margin17.20% RSI (14)60.07 Volatility1.63% 1.17%
OptionableYes Debt/Eq0.39 EPS Q/Q-10.90% Profit Margin13.60% Rel Volume0.68 Prev Close81.18
ShortableYes LT Debt/Eq0.23 EarningsJul 19 BMO Payout93.90% Avg Volume2.12M Price81.39
Recom2.40 SMA202.75% SMA504.91% SMA2002.22% Volume82,273 Change0.26%
Apr-12-16Downgrade Morgan Stanley Equal-Weight → Underweight
Mar-23-16Downgrade Leerink Partners Outperform → Mkt Perform
Jun-22-15Upgrade Bryan Garnier Neutral → Buy
Nov-16-09Initiated Deutsche Securities Buy
Nov-12-09Initiated Barclays Capital Underweight $48
Sep-30-09Upgrade Citigroup Hold → Buy
Sep-15-09Upgrade Jefferies & Co Hold → Buy
Jul-17-09Upgrade JP Morgan Neutral → Overweight
Mar-17-09Initiated Credit Suisse Neutral
Feb-27-09Reiterated Credit Suisse Neutral $14 → $7
Jan-26-09Initiated Jefferies & Co Hold
Sep-23-08Upgrade Credit Suisse Underperform → Neutral
Aug-06-08Downgrade JP Morgan Overweight → Neutral
Jun-12-08Downgrade HSBC Securities Neutral → Underweight $52 → $49
Jun-04-08Upgrade Cowen & Co Neutral → Outperform
May-09-08Upgrade Bernstein Mkt Perform → Outperform
Apr-08-08Downgrade Bear Stearns Outperform → Peer Perform
Feb-29-08Initiated Cowen & Co Neutral
Feb-29-08Downgrade HSBC Securities Neutral → Underweight
Sep-06-07Initiated UBS Buy
Jun-29-16 06:20PM  Xencor Stock Up On Cancer Drugs Partnership with Novartis
09:08AM  Inside the CHMPs Refusal of Novartiss Arzerra as a Maintenance Treatment
07:00AM  5 Wide-Moat Stocks Now Selling at a Discount at Morningstar
Jun-28-16 06:23PM  Xencor signs cancer-drug deal with Novartis; its stock surges 32% at Los Angeles Times
04:31PM  Novartis, Xencor Ink $2.4 Billion Licensing Deal In Blood Cancer
03:43PM  Why Xencor Inc's Shares Are Skyrocketing Today at Motley Fool
03:32PM  Novartis AG :NVS-US: Earnings Analysis: Q1, 2016 By the Numbers : June 28, 2016
11:06AM  Mylans Key Developments and Big Plans: What You Should Know
01:34AM  Novartis and Xencor enter into bispecific antibody agreement
Jun-27-16 08:52PM  Why a Bipartisan Bill Is Pitting the Biopharma Industry Against Itself at Fortune
Jun-24-16 06:07PM  Incyte Gains on Jakafi's Breakthrough Status for Acute GVHD
05:21PM  Brexit Sell-Off Hits 3 Big Pharma Bargain Stocks at Motley Fool
12:17PM  Genmab/Novartis' Arzerra Gets Unfavorable CHMP Opinion
01:11AM  Is this the drug answer to Alzheimer's and Huntington's disease? at
Jun-23-16 06:55AM  Five companies that could buy Ariad this year for as much as $2.9B at
Jun-21-16 05:40PM  Why Biogen Inc. Is Down 22.5% In 2016 at Motley Fool
Jun-20-16 09:06AM  CORRECTED (OFFICIAL)-Novartis aims to nearly triple biosimilar drugs on market by 2020 Reuters
Jun-19-16 06:01PM  Novartis aims to nearly triple biosimilar drugs on market by 2020 Reuters
Jun-18-16 11:00AM  Meet the Marijuana Industry Money-Man, Rob Hunt of Tuatara Capital
Jun-15-16 05:00PM  Ultimate Stock-Pickers: Active Management Not for All at Morningstar
Jun-13-16 11:58AM  Pfizer, Merck, Other Big Pharmas Likely to Acquire Marijuana-Based Drug Companies
Jun-10-16 03:05PM  Colombia Makes Good On Its Threat Against Novartis AG (NVS) at Insider Monkey
11:19AM  Novartis Reports Positive Data on Biosimilar Candidates
09:06AM  An Inside Look at Incytes Product Portfolio
Jun-09-16 06:22PM  Novartis (NVS) Announces Positive Results on Migraine Drug
06:15PM  Colombia to force Novartis to lower prices of cancer drug
05:56PM  Colombia to set new price for Novartis cancer drug -minister Reuters
04:40PM  Why Ophthotech Corp. Shares Soared 14.9% in May at Motley Fool
10:27AM  Here's Why Array Biopharma Inc. Gained 18.1% in May at Motley Fool
Jun-08-16 05:25PM  Good news, migraine sufferers! Amgen just posted positive data for its drug at CNBC
05:09PM  AbbVie Stock Downgraded As Worlds Best-Selling Drug Faces Rivals
04:48PM  Amgen says migraine prevention drug meets main goal of study
03:45PM  Exelixis, Inc. Setting New Standard of Care at Motley Fool
12:06PM  What Are the Changes in AstraZenecas Profitability?
Jun-06-16 04:44PM  Novartis (NVS) Announces Data on Leukemia Drug Tasigna
04:18PM  Exelixis, Inc. Gets Some ASCO Love at Motley Fool
01:20PM  Novartis study shows skin cancer combo also works on lungs Reuters
09:07AM  AstraZenecas Key Focus: Oncology
08:01AM  Trending Now: NVS
Jun-05-16 11:49AM  How Mylan Is Taking On One of the Worlds Top Breast Cancer Drugs at Fortune
06:42AM  Better Buy: Eli Lilly and Company vs. Pfizer at Motley Fool
Jun-04-16 02:01PM  3 Biotechs Expecting Market-Moving Trial Results Soon at Motley Fool
Jun-02-16 07:00AM  Independence of compliance reviews is questioned in drug firm settlements Reuters
04:05AM  Novartis CEO on Why the Firm Just Opened a Major R&D Facility in China at Fortune
02:25AM  Facing rival drugs, Novartis gets win with Afinitor in Europe Reuters
Jun-01-16 12:59PM  Novartis Cements China Plans as $1 Billion Research Center Opens at Bloomberg
09:35AM  [$$] Novartis boss says China will continue to outstrip Europe and US at Financial Times
May-31-16 12:52PM  The Sad and Inspiring Reason This Top Novartis Exec Stepped Down at Fortune
08:26AM  Pharma Giant Novartis Is a Great Bargain for Investors
May-30-16 08:22AM  These 5 Big Pharma Stocks Are Ridiculously Cheap at Motley Fool
May-28-16 02:18PM  Bet You Can't Guess Which of These 10 Big Pharma Names Has the Largest Late-Stage Pipeline at Motley Fool
08:07AM  3 Growth Stocks to Buy in June at Motley Fool
May-27-16 04:31PM  Roche/Biogen Drug Gazyva Beats Rituxan In Cancer Trial
03:31PM  This New Data Could Push Exelixis' Cabometyx Over $1 Billion in Peak Annual Sales at Motley Fool
10:01AM  Interested in Medivation? Take a Number! at Motley Fool
May-26-16 09:09AM  Pfizer Offers Hope For Lower-Priced Cancer Drug Combos at Forbes
May-25-16 09:41AM  Novartis' CEO Says Company Open To Selling Its $14 Billion Stake In Roche 'If The Opportunity Were Right'
05:43AM  Novartis willing to sell Roche stake without demanding premium - CEO Reuters
May-24-16 05:20PM  Novartis Filing for MabThera Biosimilar Accepted in the EU
04:48PM  PDLs Next Acquisition Target Focus Is on Hypertension
10:25AM  The Top 5 Johnson & Johnson Shareholders (JNJ) at Investopedia
09:04AM  The Best Buys in Biopharma Today at Motley Fool
May-23-16 03:47PM  Novartis' Cardiovascular Drug Gets Positive Recommendation
12:32PM  The Impact of Novartis' New Business Model (NVS) at Investopedia
11:58AM  Novartis executive exodus complicates drugmaker's rebuilding job
May-21-16 11:06AM  Struggling Novartis heart drug boosted by new medical guidelines Reuters
May-20-16 09:35PM  [$$] Colombia Threatens to Override Novartiss Patent on Gleevec at The Wall Street Journal
06:00PM  New medical guidelines back use of Novartis heart failure drug Reuters
May-19-16 11:24AM  Will These Game-Changing Cancer Treatments Hit the Market in 2016? at Motley Fool
10:20AM  Novartis launches new Entresto trials in bid to boost sales Reuters
10:04AM  Novartis Announces The Establishment Of FortiHFy, But What Is It?
06:00AM  The Real Reason Big Pharma Wants to Help Pay for Your Prescription at Bloomberg
May-18-16 05:47PM  Colombia battles world's biggest drugmaker over cancer drug
02:57PM  Novartis (NVS) to Stop Trial on Breast Cancer Drug Early
02:06PM  Behind Amgens Plans to Penetrate the Migraine Segment
12:18PM  NT Pharma's Acquisition of Novartis's Well-known International Orthopedic Brand Miacalcic Helps to Enrich Product Portfolio and Enhance Profitability ACN Newswire
07:20AM  Colombia Is Threatening Novartis Over This Cancer Drugs High Price at Fortune
12:17AM  Novartis Pharmaceuticals Head to Depart Amid Restructuring at The Wall Street Journal
May-17-16 03:20PM  Novartis splits drugs business into two, pharma chief to leave
03:17PM  [$$] Novartis to Split Drug Division at The Wall Street Journal
11:47AM  Novartis Splits Up Drug Unit as Top Executive Will Depart at Bloomberg
May-16-16 02:54PM  Pfizer buying skin drug maker Anacor for $5.2 billion AP
11:50AM  3 things you should know about Greater Washingtons bioscience companies at American City Business Journals
09:43AM  Novartis (NVS) Releases Positive Data on Ultibro Breezhaler Zacks
May-13-16 10:15AM  Parsing the Rapidly Changing Landscape of the $300 Billion Pharmaceutical Sector at TheStreet
May-11-16 01:05AM  Analyzing the Changes in Novartiss Valuation for 1Q16 Market Realist
May-09-16 04:07PM  Pfizers 1Q16 Earnings: Products That Saw Sales Drop Market Realist
03:55PM  Momenta Pharmaceuticals: Waiting for Fewer Injections at Motley Fool
May-08-16 08:15PM  3 Catalysts That Will Drive AERI Higher in 2015 (AERI, VRX) at Investopedia
May-06-16 10:39AM  This CEO of a small Boston biotech earned more than the CEOs of Novartis, Roche at American City Business Journals
May-04-16 04:05PM  Alcon Continued the Declining Trend in Its 1Q16 Earnings Market Realist
May-03-16 08:30PM  As Google's secretive biotech spinoff ramps up, look who it's hiring at American City Business Journals
08:24AM  [$$] Shannon Klinger to Replace Eric Cornut as Novartis's Ethics Officer at The Wall Street Journal
07:26AM  Move over, wearables. Swallowable computing has arrived at CNBC
May-02-16 04:51PM  Radius Health (RDUS): Stock to Surprise in Q1 Earnings? Zacks
11:21AM  The Single Most Important Thing About GlaxoSmithKline's Q1 Report at Motley Fool
11:06AM  2 Dirt-Cheap Big Pharma Stocks Poised to Beat Biotech's Bad Rap at TheStreet
Apr-28-16 01:36PM  ETFs with exposure to Novartis AG : April 28, 2016 at Capital Cube
10:06AM  Tysabri Reports Strong Patient Growth in 1Q16 Market Realist
Apr-27-16 11:06AM  Analysts Recommendations: Most Rate Novartis a Buy Market Realist
Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. It operates through three segments: Pharmaceuticals, Alcon, and Sandoz. The Pharmaceuticals segment offers patented prescription medicines for oncology, neuroscience, retina, immunology and dermatology, respiratory, cardio-metabolic, established medicines, and cell and gene therapies. The Alcon segment provides eye care products, including ophthalmic surgical equipment, instruments, disposable products, and intraocular lenses; medicines to treat chronic and acute diseases of the eye, and over-the-counter medicines for the eye; and contact lenses and lens care products. The Sandoz segment offers generic prescription medicines that include active ingredients and finished dosage forms of pharmaceuticals for dermatology, respiratory and ophthalmic, cardiovascular, metabolism, central nervous system, pain, gastrointestinal, and hormonal therapies; active pharmaceutical ingredients and intermediates primarily antibiotics; protein or other biotechnology-based products; and cytotoxic products for the hospital markets, as well as biotechnology manufacturing services to other companies. The company has collaboration and licensing agreements with Intellia Therapeutics for the discovery and development of new medicines using CRISPR genome editing technology; and with Caribou Biosciences for the development of drug discovery tools. Novartis AG was founded in 1895 and is headquartered in Basel, Switzerland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Novartis Institutes for BioMed10% OwnerMay 11Buy18.00277,7774,999,9865,573,658May 11 06:57 PM
Novartis Bioventures Ltd10% OwnerApr 12Buy10.00300,0003,000,0002,310,924Apr 12 05:09 PM
Novartis Bioventures Ltd10% OwnerFeb 17Buy8.00375,0003,000,0001,873,791Feb 17 06:47 PM